Payment overview · 2025
General Payments
$986.99
38 reported records · 9 companies
Healthcare provider profile · identity verified
Robert Marquinez, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · EAGLE PASS, TX · NPI 1407910714
Verified facts
What the public records show
CMS Open Payments records show Robert Marquinez, M.D. received $986.99 in general payments during 2025 across 38 reported records.
Novo Nordisk Inc accounted for 36.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Linzess, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 160 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 220 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 292 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $359.98 | 36.5% | 12 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $314.85 | 31.9% | 10 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $151.70 | 15.4% | 9 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $56.69 | 5.7% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $34.98 | 3.5% | 2 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $20.26 | 2.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $19.24 | 1.9% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $15.78 | 1.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.51 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $986.99 | 38 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $174.25 | 7 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $112.46 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $110.89 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $77.70 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $71.92 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $60.38 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $56.69 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $34.98 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $34.98 | 2 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $34.98 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $34.50 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $28.83 | 4 | 2025 |
Source payment records
|
|||||
| BEYFORTUS Normalized: beyfortus |
Biological | SANOFI PASTEUR INC. | $20.26 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $20.26 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $20.26 | 1 | 2025 |
Source payment records
|
|||||
| MENQUADFI Normalized: menquadfi |
Biological | SANOFI PASTEUR INC. | $20.26 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $19.24 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $17.96 | 1 | 2025 |
Source payment records
|
|||||
| ROTATEQ Normalized: rotateq |
Biological | Merck Sharp & Dohme LLC | $17.02 | 1 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | Merck Sharp & Dohme LLC | $17.02 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $15.78 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 220 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 104 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 160 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 292 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
160 | 64 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
220 | 66 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
104 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
104 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
292 | 62 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
56 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1508 | 452 |
| Losartan Potassium | Losartan Potassium | 790 | 245 |
| Amlodipine Besylate | Amlodipine Besylate | 746 | 232 |
| Carvedilol | Carvedilol | 349 | 110 |
| Levothyroxine Sodium | Levothyroxine Sodium | 347 | 103 |
| Gabapentin | Gabapentin | 335 | 119 |
| Pantoprazole Sodium | Pantoprazole Sodium | 332 | 124 |
| Metformin Hcl | Metformin Hcl | 307 | 99 |
| Ozempic | Semaglutide | 292 | 62 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 292 | 92 |
| Lisinopril | Lisinopril | 290 | 89 |
| Enalapril Maleate | Enalapril Maleate | 244 | 65 |
| Ibuprofen | Ibuprofen | 241 | 78 |
| Metoprolol Succinate | Metoprolol Succinate | 238 | 74 |
| Farxiga | Dapagliflozin Propanediol | 220 | 66 |
| Omeprazole | Omeprazole | 206 | 68 |
| Metformin Hcl Er | Metformin Hcl | 204 | 68 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 197 | 68 |
| Tramadol Hcl | Tramadol Hcl | 170 | 33 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 169 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 163 | 64 |
| Linzess | Linaclotide | 160 | 64 |
| Citalopram Hbr | Citalopram Hydrobromide | 150 | 48 |
| Furosemide | Furosemide | 150 | 60 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 143 | 58 |
| Clopidogrel | Clopidogrel Bisulfate | 142 | 44 |
| Hydralazine Hcl | Hydralazine Hcl | 141 | 45 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 139 | 39 |
| Fluticasone Propionate | Fluticasone Propionate | 131 | 54 |
| Montelukast Sodium | Montelukast Sodium | 125 | 43 |
| Januvia | Sitagliptin Phosphate | 124 | 34 |
| Alendronate Sodium | Alendronate Sodium | 116 | 43 |
| Glipizide | Glipizide | 114 | 40 |
| Tizanidine Hcl | Tizanidine Hcl | 111 | 39 |
| Simvastatin | Simvastatin | 110 | 37 |
| Famotidine | Famotidine | 107 | 47 |
| Celecoxib | Celecoxib | 106 | 33 |
| Jardiance | Empagliflozin | 104 | 29 |
| Finasteride | Finasteride | 98 | 32 |
| Meloxicam | Meloxicam | 98 | 38 |
| Pregabalin | Pregabalin | 95 | 16 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 91 | 74 |
| Meclizine Hcl | Meclizine Hcl | 89 | 39 |
| Nifedipine Er | Nifedipine | 88 | 30 |
| Eliquis | Apixaban | 87 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 87 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 87 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 86 | 25 |
| Glipizide Er | Glipizide | 84 | 30 |
| Tradjenta | Linagliptin | 82 | 23 |
| Naproxen | Naproxen | 81 | 40 |
| Tresiba Flextouch U-200 | Insulin Degludec | 81 | 22 |
| Atenolol | Atenolol | 78 | 22 |
| Trazodone Hcl | Trazodone Hcl | 76 | 30 |
| Valsartan | Valsartan | 75 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 73 | 23 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 72 | 28 |
| Donepezil Hcl | Donepezil Hcl | 72 | 25 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 67 | 21 |
| Vascepa | Icosapent Ethyl | 64 | 23 |
| Hydrocortisone | Hydrocortisone | 62 | 29 |
| Pioglitazone Hcl | Pioglitazone Hcl | 60 | 19 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 59 | 58 |
| Rybelsus | Semaglutide | 56 | 20 |
| Sertraline Hcl | Sertraline Hcl | 56 | 20 |
| Tresiba Flextouch U-100 | Insulin Degludec | 54 | 16 |
| Cephalexin | Cephalexin | 53 | 47 |
| Potassium Chloride | Potassium Chloride | 53 | 25 |
| Alprazolam | Alprazolam | 52 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 52 | 14 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 49 | 14 |
| Azithromycin | Azithromycin | 47 | 43 |
| Allopurinol | Allopurinol | 45 | 14 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 45 | 15 |
| Ondansetron Odt | Ondansetron | 43 | 22 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 41 | 22 |
| Incontrol Pen Needle | Pen Needle, Diabetic | 40 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 39 | 16 |
| Ventolin Hfa | Albuterol Sulfate | 39 | 21 |
| Ezetimibe | Ezetimibe | 38 | 13 |
| Telmisartan | Telmisartan | 38 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 37 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 37 | suppressed |
| Lovastatin | Lovastatin | 36 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 35 | 18 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 35 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 35 | 11 |
| Cilostazol | Cilostazol | 34 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 34 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 33 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 33 | 14 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Myrbetriq | Mirabegron | 33 | 13 |
| Nitroglycerin | Nitroglycerin | 33 | 18 |
| Lactulose | Lactulose | 32 | 12 |
| Dexlansoprazole Dr | Dexlansoprazole | 30 | suppressed |
| Mounjaro | Tirzepatide | 30 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 29 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 28 | 15 |
| Spironolactone | Spironolactone | 28 | suppressed |
| Prednisone | Prednisone | 27 | 14 |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Synthroid | Levothyroxine Sodium | 26 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 25 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 25 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 25 | suppressed |
| Xifaxan | Rifaximin | 25 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Ultiguard Safepack-Pen Needle | Pen Needle, Diabetic,disp Unit | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 11 |
| Dilt-Xr | Diltiazem Hcl | 20 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Clotrimazole | Clotrimazole | 19 | 12 |
| Clonazepam | Clonazepam | 18 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | suppressed |
| Levemir Flexpen | Insulin Detemir | 16 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Ramelteon | Ramelteon | 16 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 16 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 15 | suppressed |
| Prolia | Denosumab | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 14 | suppressed |
| Captopril | Captopril | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Belsomra | Suvorexant | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 13 |
| Dapagliflozin | Dapagliflozin Propanediol | 13 | 13 |
| Estarylla | Norgestimate-Ethinyl Estradiol | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Silodosin | Silodosin | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 11 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $986.99 · 38 records | Novo Nordisk Inc | AIRSUPRA, BEYFORTUS, BREZTRI, CAPVAXIVE, ENFLONSIA, FARXIGA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, FREESTYLE LIBRE 3, GARDASIL 9, JARDIANCE, Kerendia, LINZESS, MENQUADFI, MOUNJARO, Ozempic, ROTATEQ, VAXELIS, VAXNEUVANCE, Wegovy, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error